Skip to main content

CTOS 2025 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Lalith Akella, MD

Parabilis Medicines

Poster(s):

(P 415) A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)